RE:Let's be more balanced and positiveWhat we do know is that Gilles is in the catbird seat at both companies and wants CZO on NASDAQ ahead of key events expected this year. He should know the deal terms being discussed for AEZS's diagnostic. The clinical trial for the diagnostic was expected to be fully enrolled by the end of 2023. Ronnie Miller, arguably the most important biotech executive in Canada in the last 20 years, is "thrilled" about the merger. He along with Gilles should know where PGX, etc., stands; including potential deals given discussions CZO has held. Dr. Li is an accomplished scientist. The merger gets CZO on NASDAQ ahead of events and fully finances CZO's near-term revenue generation pipeline. It gives CZO cash to enter PGX deals in a position of strength. Key events ahead.
"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business..." news release
The path to a long-term sustainable business is key.
The merger provides capital and internal capabilities from AEZS to "fully support" CZO's near-term revenue generatng development programs. Gilles Gagnon, Chief Executive Officer of Ceapro: “The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs..." news release Given H.C. Wainwright's US$15 target and that it is a merger of equals the target valuation of this deal is arguably C$200 million or ~$1.25 per current CZO share.
The path,
the daisy chain of events that will define this merger...
AEZS's diagnostic test clinical trial results for children
Launch of powder formulations of CZO's two active ingredients(beta glucan, avenanthramide)
CZO's main client returns
AEZS's diagnostic continuing roll-out for adults
FDA approval for the test for children
Licensing deal for the diagnostic test for North America
Commissioning of 5X PGX scale-up
Commissioning of 10X scale-up to decision point for mass industrialization of PGX
PGX licensing deal
Immune booster plant
Phase I avenanthramide clinical trial results
Wound healing results
Wound healing partnership
Fibrosis clinical trial 'go'/'no go' decision and regulatory filing
Phase IIa avenanthramide clinical trial results
Avenanthramide pill partnership
AIM Biologicals 'go'/'no go' clinical trial decision
SoperRiver wrote: A lash-up wuth AEZS has to be viewed positively for CZO's future and for current Shareholder investments and holdings. The Plan of Arrangement is very detailed including a Fairness Opinion from a reputable Firm. Regretably the Exchnage Ratio was negatively affected as Shareholders sold-off as Sales to the main Distributor for reasons of a corporate retstructuring at its major Client that porbably overstocked product ahead of time. CZO's products remain very valuable and as orders are reestarted Revenues are bound to rebound. This transaction is an opportunity for CZO to fiinally move forward with its pipeline (eg PGX) with the infusion of capital and to take advantage of the already on-the-market products of AEZS. Listing on Nasdaq opens up a whole new set of Investors that won't or are not permitted to trade on TSXV. Trading multipoles are a whole differnt ball game on that exchnage. Hopefully Shareholders will see that the vitriol levelled at Management and the Board adds little to a meaningful discussion and rather focus on something opening up many new opportunities for CZO. Getting on with the Transaction seems to make a lot of sense.